Exploring the molecular biomarker utility of circCCT3 in multiple myeloma: A favorable prognostic indicator,

Maria Papatsirou1, Christos K Kontos1, Ioannis Ntanasis-Stathopoulos2

  • 1Department of Biochemistry and Molecular Biology, Faculty of Biology National and Kapodistrian University of Athens Athens Greece.

Hemasphere
|March 4, 2024
PubMed

Insights

Circular RNA CCT3 (circCCT3) is elevated in multiple myeloma (MM) patients, correlating with better survival outcomes. High circCCT3 expression may serve as a key prognostic biomarker for MM progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Circular RNAs (circRNAs) play a role in multiple myeloma (MM) pathobiology.
  • circCCT3 has been implicated in MM development and progression via microRNA sponging.

Purpose of the Study:

  • To investigate circCCT3 expression levels in smoldering and symptomatic MM.
  • To evaluate the clinical significance and prognostic value of circCCT3 in MM patients.

Main Methods:

  • Developed and optimized a nested real-time quantitative PCR assay for circCCT3.
  • Analyzed circCCT3 expression in CD138+ plasma cells from 145 MM and smoldering MM patients.
  • Correlated circCCT3 levels with clinical parameters and patient survival.

Main Results:

  • Significantly higher circCCT3 expression was observed in MM patients compared to smoldering MM patients.
  • Elevated circCCT3 levels were associated with longer progression-free and overall survival.
  • Prognostic significance of circCCT3 was independent of disease stage (ISS, R-ISS) and patient age.

Conclusions:

  • circCCT3 is a promising molecular biomarker for predicting prognosis in multiple myeloma.
  • circCCT3 may be particularly useful for prognostic assessment in R-ISS stage II MM patients.

Related Concept Videos